International Journal of Antimicrobial Agents最新文献

{"title":"George K. Daikos (1918 – 2025)","authors":"George L Daikos , George L. Petrikkos","doi":"10.1016/j.ijantimicag.2025.107559","DOIUrl":"10.1016/j.ijantimicag.2025.107559","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 4","pages":"Article 107559"},"PeriodicalIF":4.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative epidemiology and resistance mechanisms of carbapenem-, tigecycline-, and polymyxin-resistant Enterobacteriaceae in pediatric diarrhoea, 2017 and 2023","authors":"Jing Zhang ,&nbsp;Hanyu Wang ,&nbsp;Yingling Ni ,&nbsp;Zelin Yan ,&nbsp;Dan Chi ,&nbsp;Kewei Li ,&nbsp;Rong Zhang","doi":"10.1016/j.ijantimicag.2025.107580","DOIUrl":"10.1016/j.ijantimicag.2025.107580","url":null,"abstract":"<div><h3>Objectives</h3><div>To compare the epidemiology and resistance mechanisms of carbapenem-, tigecycline-, and polymyxin-resistant <em>Enterobacteriaceae</em> isolated from pediatric diarrhoea cases in 2017 and 2023.</div></div><div><h3>Methods</h3><div>Fecal samples from children with diarrhoea were collected in Zhejiang, China, in 2017 and 2023. Bacterial isolation, antimicrobial susceptibility testing, and whole-genome sequencing were performed to identify resistance determinants and plasmid types.</div></div><div><h3>Results</h3><div>The prevalence of <em>mcr-1</em>-positive strains declined significantly from 2.36% (25/1059) in 2017 to 0.82% (3/367) in 2023, while <em>tet</em>(X4)-positive strains rose from 0% to 1.91% (7/367). Carbapenemase-producers remained rare (0.28% in 2017; 1.63% in 2023), with <em>bla</em>_NDM as the dominant carbapenemase gene. Whole genome sequencing revealed diverse antimicrobial resistance genes (ARGs) and evolving plasmid types. Notably, by 2023, all <em>mcr-1</em> were carried on IncI2 plasmids. Conjugation experiments confirmed plasmids carrying <em>mcr-1, bla</em>_NDM-5, and <em>tet</em>(X4) are transferable to a recipient strain.</div></div><div><h3>Conclusions</h3><div>The rising prevalence of multidrug-resistant Enterobacteriaceae in pediatric diarrhoea highlights the urgent need for continuous surveillance and effective infection control measures.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 5","pages":"Article 107580"},"PeriodicalIF":4.6,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes to phage therapy among Australian infectious diseases physicians","authors":"Martin Plymoth ,&nbsp;Stephanie A. Lynch ,&nbsp;Ameneh Khatami ,&nbsp;Holly A. Sinclair ,&nbsp;David L. Paterson ,&nbsp;Jessica C. Sacher ,&nbsp;Jan Zheng ,&nbsp;Ruby CY. Lin ,&nbsp;Jonathan R. Iredell","doi":"10.1016/j.ijantimicag.2025.107579","DOIUrl":"10.1016/j.ijantimicag.2025.107579","url":null,"abstract":"<div><h3>Background</h3><div>Due to the rise in antimicrobial resistance, there has been an increased interest in phage therapy to treat multidrug-resistant infections. In Australia, phage therapy is predominantly used in small clinical studies or for compassionate use; however, despite its potential expansion in modern medicine, the perception of phage therapy among medical professionals remains largely unknown.</div></div><div><h3>Methods</h3><div>We conducted a national survey of Australian infectious diseases and clinical microbiology advanced trainees and specialists using an online mailing list to assess their knowledge, areas of interest, and concerns around the use of phage therapy in clinical practice in Australia; with 92 eligible respondents.</div></div><div><h3>Results</h3><div>Most respondents believed that the current national plan for controlling antimicrobial resistance is inadequate and that phage therapy may be an effective solution; with 87 (97%) indicating that they would consider using phage therapy meeting established guidelines for purity and safety. There was a preference for bespoke therapy, with Gram-negative pathogens highlighted as priority targets. Alongside the phage therapy delivery protocols, therapeutic phage monitoring was considered important. Cystic fibrosis, lung-infections, prosthetic device/related infections, and infections among patients following transplantation and/or immunosuppression were highly ranked in terms of priorities for clinical syndromes. Accessibility was highlighted as a barrier to phage therapy, specifically, timely access (<em>n</em> = 66; 72%) and logistics of phage procurement and administration (<em>n</em> = 64; 70%).</div></div><div><h3>Conclusions</h3><div>These results suggest the support of phage therapy among infectious diseases and clinical microbiology advanced trainees and specialists in Australia, and highlights areas of focus and priority in order to advance phage therapy.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 5","pages":"Article 107579"},"PeriodicalIF":4.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal analysis of carbapenem-resistant Escherichia coli in a Southern Chinese hospital (2015–2021): Epidemiology, genetics, and resistance mechanisms","authors":"Zhuo-Cheng Yao ,&nbsp;Yao Sun ,&nbsp;Zhe-xiao Ma ,&nbsp;Huan-chang Chen ,&nbsp;Qing-xia Fu ,&nbsp;Ping Xia ,&nbsp;Jing-chun Kong ,&nbsp;Jia Zhang ,&nbsp;Tie-Li Zhou ,&nbsp;Chang-rui Qian","doi":"10.1016/j.ijantimicag.2025.107577","DOIUrl":"10.1016/j.ijantimicag.2025.107577","url":null,"abstract":"<div><div>This study conducted a retrospective genomic and epidemiological analysis of <em>Escherichia coli</em> (CREC) in a large general hospital in southern China. From 2015–2021, the characteristics of 183 CREC strainswere determined via minimum inhibitory concentration (MIC) determination and whole-genome sequencing (WGS). The carbapenem resistance mechanisms of carbapenemase-producing carbapenem-resistant <em>E.coli</em> (CP-CREC) and non-carbapenemase-producing carbapenem-resistant <em>E. coli</em> (non-CP-CREC) were investigated through a combination of porin genes (<em>ompC</em>/<em>ompF</em>) assessment and antimicrobial resistance gene detection/copy number quantification. We observed a diverse population structure of CREC, with a total of 60 different sequence types (STs) assigned. A total of 48.6% (89/183) of theisolates were extraintestinal pathogenic <em>E. coli</em>, including the first reported O16-ST131 strains carrying carbapenem resistance genes. Adhesion and invasion experiments revealed that the O16-ST131 CP-CREC strains had strong adhesion and invasion abilities. The majority of CREC strains (90.2%, 165/183) were predicted to have reduced expression of at least one outer membrane porin gene (<em>ompC</em>/<em>ompF</em>). Compared with CP-CREC, non-CP-CREC presented significantly higher copy numbers of extended-spectrum β-lactamase (ESBL) genes (median copy number variants = 3.635 × , <em>P</em> ＜0.001) and <em>ampC</em> genes (median copy number variants: 2.80 × , <em>P</em> = 0.022). High-risk clones (i.e., ST131, ST410, and ST167) persisted long term in the hospital through both CP-CREC and non-CP-CREC forms. Genetic environment analysis revealed that <em>bla</em>_NDM was located in a conserved genetic environment (<em>dsbD</em> - <em>trpF</em> - <em>bla</em>_NDM). This work provides a comprehensive description of CREC and offers new insights into CREC surveillance based on WGS in China.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 5","pages":"Article 107577"},"PeriodicalIF":4.6,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In reply to the letter to the editor regarding ‘battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin’","authors":"Fatma Nisa Ballı Turhan ,&nbsp;Pınar Bakır Ekinci ,&nbsp;Melek Kurtaran ,&nbsp;Emre Kara ,&nbsp;Gülçin Telli Dizman ,&nbsp;Meliha Çağla Sönmezer ,&nbsp;Mutlu Hayran ,&nbsp;Kutay Demirkan ,&nbsp;Gökhan Metan","doi":"10.1016/j.ijantimicag.2025.107576","DOIUrl":"10.1016/j.ijantimicag.2025.107576","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 4","pages":"Article 107576"},"PeriodicalIF":4.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic insights into nontyphoidal Salmonella: Prediction of antimicrobial resistance with whole genome-based machine learning","authors":"Pei Yee Woh ,&nbsp;Fadjar Soengkono ,&nbsp;Yehao Chen ,&nbsp;Zati Hakim Azizul Hasan ,&nbsp;Siti Nursheena Mohd Zain ,&nbsp;Jose Quiroga ,&nbsp;Kevin Wing Hin Kwok","doi":"10.1016/j.ijantimicag.2025.107575","DOIUrl":"10.1016/j.ijantimicag.2025.107575","url":null,"abstract":"<div><h3>Background</h3><div>Nontyphoidal <em>Salmonella</em> is a world-leading foodborne pathogen associated with an increased rate of antimicrobial resistance (AMR) and remains endemic in Asia. Utilizing whole genome sequencing (WGS) could significantly contribute to AMR prediction, from bioinformatic phylogenomic analysis to the advancement of machine learning (ML), leading towards automated AMR diagnostic.</div></div><div><h3>Methods</h3><div>We obtained the <em>Salmonella</em> WGS from the National Centre for Biotechnology Information database and analysed their resistance profiles. We extracted, transformed, and labelled the resistance data with one-hot encoding platform for eXtreme Gradient Boosting (XGBoost) and convolutional neural network (CNN) model construction, training, and evaluation.</div></div><div><h3>Results</h3><div>We selected a total of 788 <em>Salmonella</em> isolates associated with resistance genotype and phenotype data. These isolates had high resistance to aminoglycoside, beta-lactam, phenicol, quinolone, sulphonamide, tetracycline, and trimethoprim. <em>S</em>. Weltevreden ST365 (<em>n</em> = 121) was the most common serovar with the highest occurrence in food products. Through ML, both XGBoost and CNN models enabled highly accurate AMR prediction with performance accuracy of 0.97625 and 0.9904, respectively. Moreover, the interpretation of Shapley Additive exPlanations values uncovers the most valuable genomic features and associated genes for each antimicrobial agent tested.</div></div><div><h3>Conclusions</h3><div>Our study provides new knowledge in demonstrating the AMR phylogeographical relatedness and AMR prediction through XGBoost and CNN with competitive performance. Hence, WGS-based ML prediction and its machine application could be promoted as a promising tool for AMR work in food safety and public health settings.</div></div><div><h3>Video Abstract</h3><div><span><span><span><span><video><source></source></video></span><span><span>Download: <span>Download video (5MB)</span></span></span></span></span></span></div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 5","pages":"Article 107575"},"PeriodicalIF":4.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page & Editorial Board","authors":"","doi":"10.1016/S0924-8579(25)00127-X","DOIUrl":"10.1016/S0924-8579(25)00127-X","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 3","pages":"Article 107572"},"PeriodicalIF":4.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical application of customized and non-customized bacteriophage therapy in patients with refractory/resistant bacterial infections: A systematic review and meta-analysis","authors":"Yang Liu ,&nbsp;Shuhua Thong ,&nbsp;Wilfried Moreira ,&nbsp;Jia Hao Yeo ,&nbsp;Yang Zhong ,&nbsp;Zhi-Soon Chong ,&nbsp;Tse Hua Nicholas Wong ,&nbsp;Shimin Jasmine Chung ,&nbsp;Andrea Lay Hoon Kwa","doi":"10.1016/j.ijantimicag.2025.107570","DOIUrl":"10.1016/j.ijantimicag.2025.107570","url":null,"abstract":"<div><h3>Background</h3><div>Patients with refractory/resistant bacterial infections face high mortality rates. Bacteriophage therapy (PT) is a viable solution, but clinical evidence remains fragmented. This review synthesizes current evidence on PT efficacy, safety, and implementation, with additional analysis by customization strategies: non-customized, customized selection and customized production.</div></div><div><h3>Method</h3><div>We examined clinical studies on PTs for refractory/resistant bacterial infections and pooled efficacy and safety outcomes by customization strategy from randomized controlled trials, observational studies, cohorts, case series and case reports using a random-effects model. Subset sensitivity analyses were conducted, and individual patient data were further analysed. Risk of bias was assessed for each study.</div></div><div><h3>Result</h3><div>As of 14 May 2025, 16 226 articles were identified, and 130 studies (1115 patients) were included: 559 non-customized, 451 customized selection and 105 customized production. Risks of bias were low to serious. Clinical improvement (<em>I</em>² 87%) and bacterial eradication (<em>I</em>² 94%) rates were 71% (95% confidence interval [CI], 60–80) and 51% (95% CI 30–72), respectively. Customized production group had the highest success rates (79% and 87%), albeit at a cost. Time taken for customization often resulted in delays in PT. Higher titres and multiple administration routes were associated with better bacterial eradication. Efficacy improvement compared to control was statistically insignificant. Adverse events were mild to moderate. Phage neutralization appeared before, during, and after PT cessation. Impacts on pharmacokinetics remain uncertain. Immunological markers varied across studies.</div></div><div><h3>Conclusions</h3><div>PT shows promising clinical outcomes, but significant gaps in clinical evidence persist, warranting well-designed trials. Laboratory-based phage monitoring shows promise but requires systematic investigation.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 4","pages":"Article 107570"},"PeriodicalIF":4.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of multiplex recombinase polymerase amplification for the rapid detection of five carbapenemase (blaKPC, blaNDM, blaOXA-48-like, blaIMP, and blaVIM) and 10 mcr (mcr-1 to mcr-10) genes in blood cultures","authors":"Kittitouch Tullayaprayouch ,&nbsp;Thanawat Phuadraksa ,&nbsp;Sirirat Luk-In ,&nbsp;Sudarat Pornsuwan ,&nbsp;Phiraphat Changkhundi ,&nbsp;Sineewanlaya Wichit ,&nbsp;Sakda Yainoy","doi":"10.1016/j.ijantimicag.2025.107567","DOIUrl":"10.1016/j.ijantimicag.2025.107567","url":null,"abstract":"<div><div>The emergence of plasmid-encoded carbapenemase and mobile colistin resistance (<em>mcr</em>) genes poses a significant challenge in controlling the spread of multidrug-resistant Gram-negative bacteria. Addressing this issue requires the development of rapid, accurate, and cost-effective tools for gene detection. For the first time, this study reports three multiplex recombinase polymerase amplification (RPA) assays, each designed to detect five resistance genes: carbapenemase (<em>bla</em>_KPC, <em>bla</em>_NDM, <em>bla</em>_OXA-48-like, <em>bla</em>_IMP, and <em>bla</em>_VIM), <em>mcr</em>-1 to <em>mcr</em>-5, and <em>mcr</em>-6 to <em>mcr</em>-10. Using agarose gel electrophoresis, all 15 target genes were successfully amplified by the three assays, demonstrating the potential of these assays for integration with rapid reporting platforms. To increase their applicability, the assays were combined with SYBR^Ⓡ Green I for visual identification of all 15 target genes and with lateral flow immunoassays (LFIAs) for detection of two carbapenemase (<em>bla</em>_NDM and <em>bla</em>_OXA-48-like) and two <em>mcr</em> genes (<em>mcr</em>-1 and <em>mcr</em>-3) genes. Specificity testing showed that RPA-SYBR^Ⓡ Green I and RPA-LFIAs produced no cross-reactivity among the target genes. The limit of detection for RPA-SYBR^Ⓡ Green I, for all genes, ranged from 2 × 10⁰ to 2 × 10² CFU/reaction, and for RPA-LFIAs from 2 × 10⁰ to 2 × 10³ CFU/reaction. The developed RPA-SYBR^Ⓡ Green I and RPA-LFIAs successfully detected 15 and four target genes, from positive haemoculture bottles. These assays offer a promising approach for point-of-care testing. Providing a valuable tool for antimicrobial resistance surveillance and timely guidance for effective antibiotic intervention.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 4","pages":"Article 107567"},"PeriodicalIF":4.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteriophage-enhanced doxycycline activity against Escherichia coli in chronic bacterial prostatitis","authors":"Novella Cesta ,&nbsp;Alessandro Fusco ,&nbsp;Caterina Ferretti ,&nbsp;Alessandro Materazzi ,&nbsp;Anna Altieri ,&nbsp;Cartesio D’Agostini ,&nbsp;Marco Iannetta ,&nbsp;Massimo Andreoni ,&nbsp;Arianna Tavanti ,&nbsp;Loredana Sarmati ,&nbsp;Mariagrazia Di Luca","doi":"10.1016/j.ijantimicag.2025.107571","DOIUrl":"10.1016/j.ijantimicag.2025.107571","url":null,"abstract":"<div><h3>Objectives</h3><div>Prostatitis caused by antibiotic-resistant <em>Escherichia coli</em> poses a significant treatment challenge, and phage therapy is emerging as a promising antibacterial strategy. Here we report the case of a patient with prostatitis caused by an extended spectrum β-lactamase-producing <em>E. coli</em> successfully treated with oral doxycycline and two phage cocktails. The use of doxycycline was supported by the detection of <em>Mycoplasma</em> spp. in the patient’s urine. We also tested the same phage-antibiotic combination against a panel of different <em>E. coli</em> strains in vitro.</div></div><div><h3>Methods</h3><div>A patient received oral SES and PYO phage cocktails alongside oral doxycycline for 30 days. The MIC values of doxycycline and phages alone and in combination were evaluated by checkboard assay versus five <em>E. coli</em> isolates, including the patient’s strain. Synergy was assessed using a modified fractional inhibitory concentration index. Data were analysed by synogram and an interaction plot based on the percentage reduction of the absorbance values (OD₅₇₀) between untreated control and treated samples. Growth curves were performed over 24 h to monitor bacterial replication in the presence/absence of phage and/or antibiotic.</div></div><div><h3>Results</h3><div>After treatment microbiological cultures were negative and symptoms remitted. A synergistic/additive effect between doxycycline and the phages was observed in vitro in three out of five <em>E. coli</em> isolates. Synogram analysis showed a synergistic effect versus one strain, while an additive effect was observed for the other four isolates. Growth curve analysis demonstrated enhanced bacterial growth inhibition for up to 12 h with the combined treatment compared with either therapy alone.</div></div><div><h3>Conclusions</h3><div>Although the <em>E. coli</em> strain was resistant to doxycycline, the antibiotic was administered specifically to target the <em>Mycoplasma</em> infection. Interestingly, the enhanced in vitro activity observed when the antibiotic was combined with phages versus <em>E. coli</em> suggests that this combination may be effective at eradicating chronic prostatitis caused by extended spectrum β-lactamase-producing <em>E. coli</em>.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"66 4","pages":"Article 107571"},"PeriodicalIF":4.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}